All products sold by FfAME, Inc., are for research and development purposes only, and are not for use in humans. It is the responsibility of the buyer to determine the suitability of the product for any given purpose. Products should be handled by trained personnel who understand the potential hazards of working with such materials. Responsibility for accidents arising from the handling and use of Firebird/FfAME's products rests solely with the buyer.

Research Sumamry

Dr. Schein became a senior fellow at FfAME in 2013. She is working
together with our experts in polymerases to design and select novel
inhibitors of human enteroviruses. Dr. Schein began her career in research
and development at Biogen, producing interferons for early clinical
studies. She later became an Oberassistentin at the Swiss Federal
Institute of Technology in Zurich (ETHZ) and was an Associate Professor at
the University of Texas Medical Branch (UTMB) at Galveston until 2012. Her
major projects have ranged from studying the interaction of interferons
with ribonucleases to designing drugs against microbial pathogens. Her
group at the UTMB identified novel inhibitors of anthrax edema factor,
using computational compound selection and docking. She also developed
and validated a novel method for extracting data from large biological
sequence collections, based on determining physicochemical property (PCP)
consensus sequences. The method has proved very useful for vaccine design,
for example against Dengue virus, and to identify common properties of
allergenic proteins. All of these tools are now in use in her current
projects. Dr. Schein is a well cited author with over a hundred
publications in journals and books.